Biotech company ArcanaBio announced it was selected for funding by Denmark’s BioInnovation Institute (BII), supported by the Novo Nordisk Foundation. ArcanaBio will join BII’s Deep Tech Lab – Quantum program in Copenhagen from September 2024.
Utilizing novel nano-photonics technology coupled with AI, ArcanaBio innovative label-free liquid biopsy solution aims to enable faster, cheaper and higher-frequency protein characterization with a goal of bringing reference-grade diagnostics to the home.
The BioInnovation Institute (BII) is an initiative by the Novo Nordisk Foundation, which is a non-profit international enterprise foundation focused on accelerating world-class life science innovation. And the Deep Tech Lab – Quantum (supported by BII) is Denmark’s official NATO DIANA accelerator site, utilizing the country’s leadership in quantum science to drive dual-use innovations across the life science and defense industries.
KEY QUOTES:
“We are honoured to receive funding and to be selected to join this prestigious quantum initiative. We are at the forefront of a new biosensor revolution with a patent-pending, label-free detection technology that has been a long-sought-after advancement in proteomics. Our novel platform has potential both to enable testing laboratories to offer a wider range of biomarker services at lower cost and empower individuals to proactively monitor their health by integrating frequent, reference-quality testing into their lives.”
– Kristjan Gunnarsson, CEO of ArcanaBio
“The goal here is to rethink diagnostics. Building a new capability to track proteome dynamics can provide powerful real-time and predictive insights into health status, disease progression and epidemiology. Ultimately this can serve as an enabler of preventive healthcare — a solution to the challenge of rising societal costs.”
– Daniel Oskarsson, CTO of ArcanaBio
